Trialspark helps accelerate medical and scientific research by building software for clinical trials.
Location: United States, New York
Employees: 51-200
Total raised: $156M
Founded date: 2013
Investors 9
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.10.2021 | Series C | $156M | - |
Mentions in press and media 24
| Date | Title | Description |
| 27.06.2024 | Formation Bio: Revolutionizing Pharma with AI | Formation Bio, a NYC-based tech-driven and AI-native pharma company, recently secured a staggering $372M in Series D funding. This funding, led by a16z and with significant participation from Sanofi, marks a significant milestone for the co... |
| 26.06.2024 | Formation Bio secures $372MM Series D funding to grow drug pipeline and continue expanding AI-driven drug development platform | NEW YORK, June 26, 2024 /PRNewswire/ -- Formation Bio, a tech-driven and AI-native pharma company, announced today that it has raised $372MM of Series D financing. The financing was led by a16z with significant participation from Sanofi. Cu... |
| 19.02.2023 | ChatGPT creator Sam Altman has invested in dozens of companies over the years, from Elon Musk's Neuralink to Reddit | Sam Altman, CEO of OpenAI, has invested in scores of companies over the years. Kevin Dietsch/Getty Images OpenAI CEO Sam Altman has invested in lots of tech and energy companies. He was the lead investor in rounds for companies like Reddit,... |
| 10.01.2022 | TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio | NEW YORK, Jan. 10, 2022 /PRNewswire/ -- TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany. Sprifermin is a potential first-in-class dise... |
| 08.12.2021 | TrialSpark hires two new executives to join the company's leadership team, Gavin Corcoran, MD (Chief Medical Officer) and James Leslie, MBA (Chief Financial Officer) | NEW YORK, Dec. 8, 2021 /PRNewswire/ -- TrialSpark is building a next generation pharma company focused on bringing new treatments to patients faster and more efficiently. Despite the sweeping technological changes transforming biotech, brin... |
| 04.10.2021 | 2021 is already a record breaking year for digital health funding | Funding to digital health companies surpassed $20 billion for the first time ever COVID has taken digital health from a growing but still niche space to the mainstream. As fast as it was growing before the pandemic, it has now turned into a... |
| 02.10.2021 | US-based Clinical trials vendor TrialSpark raises USD 156 million in Series C round | TrialSpark, a New York-based biotech unicorn, raised USD 156 million in a Series C round led by tech investors Sam Altman and Lachy Groom on 1 October 2021. |
| 01.10.2021 | Tech-driven clinical trial startup TrialSpark lands $156M in Series C | Photo: franckreporter/Getty Images |
| 30.09.2021 | TrialSpark raises $156MM Series C Funding led by Sam Altman and Lachy Groom | NEW YORK, Sept. 30, 2021 /PRNewswire/ -- TrialSpark announced today that it has raised $156MM in Series C funding. Sam Altman and Lachy Groom led the round, with participation from new and existing investors, including Sequoia Capital (Seri... |
| 30.09.2021 | TrialSpark Raises $156M in Series C Funding | TrialSpark, a NYC-based next generation pharma company, raised $156MM in Series C funding. The round was led by Sam Altman and Lachy Groom, with participation from new and existing investors, including Sequoia Capital (Series A lead), Thriv... |
Show more